WP
TNGX icon

Woodline Partners’s Tango Therapeutics TNGX Stock Holding History

Woodline Partners’s Portfolio TNGX Stock Details TNGX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$125M Sell
4,000,567
-3,999,446
-50% -$98.9M 0.39% 50
2026
Q1 		$167M Sell
8,000,013
-2,072,212
-21% -$28.8M 0.63% 17
2025
Q4 		$89.2M Buy
10,072,225
+4,042,297
+67% +$34.8M 0.35% 58
2025
Q3 		$50.7M Buy
6,029,928
+22
+0% +$149 0.24% 109
2025
Q2 		$30.9M Buy
6,029,906
+5,523,718
+1,091% +$13.7M 0.16% 184
2025
Q1 		$693K Buy
506,188
+111,791
+28% +$275K ﹤0.01% 801
2024
Q4 		$1.22M Buy
+394,397
New +$1.83M 0.01% 731
2024
Q3 		– Sell
-348,091
Closed -$2.99M – 703
2024
Q2 		$2.99M Buy
+348,091
New +$2.69M 0.03% 385
2023
Q4 		– Sell
-250,000
Closed -$2.81M – 656
2023
Q3 		$2.81M Sell
250,000
-13,645
-5% -$83.2K 0.03% 369
2023
Q2 		$875K Sell
263,645
-97,549
-27% -$351K 0.01% 496
2023
Q1 		$1.43M Sell
361,194
-4,042
-1% -$23.5K 0.02% 451
2022
Q4 		$2.65M Sell
365,236
-134,859
-27% -$949K 0.04% 435
2022
Q3 		$1.81M Hold
500,095
– – 0.03% 480
2022
Q2 		$2.27M Hold
500,095
– – 0.03% 409
2022
Q1 		$3.79M Buy
500,095
+77
+0% +$667 0.06% 279
2021
Q4 		$5.47M Sell
500,018
-22
-0% -$265 0.08% 273
2021
Q3 		$6.47M Sell
500,040
-3,357
-0.7% -$40.2K 0.11% 223
2021
Q2 		$5.73M Hold
503,397
– – 0.11% 206
2021
Q1 		$5.6M Hold
503,397
– – 0.12% 180
2020
Q4 		$5.76M Buy
503,397
+3,397
+0.7% +$35.8K 0.15% 149
2020
Q3 		$5.18M Buy
+500,000
New +$5.11M 0.17% 126

Other funds holding TNGX

RI
RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
FCM
Farallon Capital Management San Francisco, California $21.7B AUM 79.24% 1-Year Est. Return
BCM
Boxer Capital Management San Diego, California $1.33B AUM 864.5% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return
TCM
TCG Crossover Management Palo Alto, California $4.16B AUM 983.43% 1-Year Est. Return
PBA
Paradigm Biocapital Advisors New York $5.34B AUM 380.18% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
SL
Siren LLC Greenwich, Connecticut $4.94B AUM 244.43% 1-Year Est. Return

Woodline Partners's TNGX Position: Q2 2026 in Review

Woodline Partners reduced its Tango Therapeutics (TNGX) stake by 50% in Q2 2026, selling an estimated $98.9M and leaving 4,000,567 shares worth $125M. The position accounts for 0.39% of the portfolio, ranked #50.

Woodline Partners first reported a position in TNGX in Q3 2020 and has held it in 21 quarters since. The position peaked at $167M in Q1 2026. 249 funds tracked by Wall St. Rank hold TNGX as of Q2 2026.

  • Woodline Partners held 4,000,567 shares of Tango Therapeutics worth $125M as of Q2 2026.
  • Woodline Partners sold 3,999,446 Tango Therapeutics shares in Q2 2026, an estimated $98.9M.
  • Tango Therapeutics made up 0.39% of Woodline Partners's portfolio in Q2 2026, its #50 holding.
  • Woodline Partners first reported a position in Tango Therapeutics in Q3 2020 and has held it in 21 quarters since.
  • Woodline Partners's Tango Therapeutics position peaked at $167M in Q1 2026.
  • 249 funds tracked by Wall St. Rank held Tango Therapeutics as of Q2 2026.

Based on Woodline Partners's 13F filing for Q2 2026, filed 14 Aug 2026.